Brexucabtagene autoleucel (Tecartus) is another anti-CD19 CAR T that was approved in 2020 for the mantle cell lymphoma (MCL) treatment and recently for ALL based on ZUMA-2 (NCT02601313) and ZUNA-3 (NCT02614066) trials [63, 64]. This evidence concerns the gene CD19 and mantle cell lymphoma.